Type II endometrial cancer. This form is not related to estrogen levels. It grows faster and has a higher chance of spreading. This group includes more aggressive cancers like uterine serous ...

By contrast, type II ECs develop in older patients, are not hormone dependent and are responsible for most recurrences and deaths from EC. Uterine serous cancer constitutes up to 10% of all ...

Uterine carcinosarcoma, also referred to as malignant mixed Müllerian tumor, is a rare and highly aggressive neoplasm predominantly affecting postmenopausal women. Combining carcinomatous and ...

Most uterine cancers have excellent five-year survival rates – up to 95% for localized cancer. Serous uterine cancer is an exception, with five-year survival rates of 35% to 50% for stage 1 or 2 ...

Uterine cancer is the fourth most common cancer among women and the most common cancer of a woman's reproductive system. There are two major types of uterine cancer: Adenocarcinoma of the endometrium: ...

For a long time, scientists thought this cancer came from the ovaries. But this new research, led by Professor Alexander ...

Both uterine serous carcinoma and carcinosarcoma are much more ... again in the p53 wild-type group. There are many issues in the treatment of patients who have mismatch repair deficiency.

Endometrial cancer is a type of tumour that arises in the tissue lining the uterus. Most endometrial cancers are adenocarcinomas; that is, cancers formed from cells that make and release mucus and ...

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 women across England ...

Women in England with a specific type of endometrial cancer will be able to access an immunotherapy for the first time, after NICE backed use of GlaxoSmithKline's PD-1 inhibitor Jemperli via the ...